Holen Sie sich die Stockscreener-App
67.75
2.40%
-1.615
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
ANI Pharmaceuticals at RBC Conference: Strategic Growth in Rare Diseases By Investing.com - Investing.com UK
Is the Options Market Predicting a Spike in ANI Pharmaceuticals (ANIP) Stock? - TradingView
ANI Pharmaceuticals To Present At RBC Capital Markets Conference; Webcast At 7:45 AM ET - Nasdaq
Zacks.com featured highlights include HIS, ANI Pharmaceuticals, Pediatrix Medical, Fresenius Medical Care and LendingTree - TradingView
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - GlobeNewswire
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st
5 Top-Ranked Mid-Cap Stocks to Buy for a Stellar Portfolio - TradingView
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross? - Zacks Investment Research
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
ANI Pharmaceuticals Launches Kionex Suspension For Electrolyte Imbalance Management: Key Trend Transforming... - WhaTech
ANI Pharmaceuticals launches generic Nitazoxanide Tablets By Investing.com - Investing.com South Africa
Ani Pharmaceuticals Launches Nitazoxanide Tablets for Treating Diarrhea -March 19, 2025 at 09:33 am EDT - MarketScreener
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets - GlobeNewswire
ANI Pharmaceuticals launches generic Nitazoxanide Tablets - Investing.com
ANI Pharmaceuticals Announces The Launch Of Nitazoxanide Tablets -March 19, 2025 at 06:51 am EDT - Marketscreener.com
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
ANI Pharmaceuticals settles royalty obligation for $17.25 million By Investing.com - Investing.com Australia
ANI Pharmaceuticals Eliminates Royalty Obligation On ILUVIEN And YUTIQ - Nasdaq
ANI Pharmaceuticals settles royalty obligation for $17.25 million - Investing.com India
ANI Pharma buys Iluvien and Yutiq royalties (ANIP:NASDAQ) - Seeking Alpha
ANI Pharma buys royalties linked to Iluvien and Yutiq - MSN
ANI Pharmaceuticals Completes Buyout of Royalty Obligation for Iluvien, Yutiq -March 18, 2025 at 08:20 am EDT - Marketscreener.com
ANI Pharmaceuticals Completes $17.25 Million Buyout of Royalty Obligation for ILUVIEN and YUTIQ - Nasdaq
ANI Pharmaceuticals Announces Buyout Of Royalty Obligation For Iluvien And Yutiq -March 18, 2025 at 06:55 am EDT - Marketscreener.com
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ® - GlobeNewswire
Jefferies Initiates Coverage of ANI Pharmaceuticals (ANIP) with Buy Recommendation - Nasdaq
Ani Pharmaceuticals sr. VP Cook sells $25,332 in stock - Investing.com India
Ani Pharmaceuticals sr. VP Cook sells $25,332 in stock By Investing.com - Investing.com South Africa
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts - Benzinga
ANI Pharma rises on expanded US approval for eye-disease drug - TradingView
ANI Pharmaceuticals Says FDA Approves Expanded Label for Iluvien -March 14, 2025 at 07:23 am EDT - Marketscreener.com
Jefferies Initiates Coverage on ANI Pharmaceuticals With Buy Rating, $80 Price Target - Marketscreener.com
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label - GlobeNewswire
ILUVIEN Scores Major FDA Win: Now Treats Two Serious Eye Conditions - StockTitan
JPMorgan Chase & Co. Begins Coverage on ANI Pharmaceuticals (NASDAQ:ANIP) - Defense World
ANI Pharma wins Overweight rating at J.P. Morgan on growth prospects - MSN
ANI Pharma stock wins J.P. Morgan bullish view (ANIP:NASDAQ) - Seeking Alpha
Exploring Growth Opportunities: Raytheon, ANI Pharmaceuticals, DeckersNews and Statistics - IndexBox, Inc.
Zacks.com featured highlights include ANI Pharmaceuticals, Dana, Pitney Bowes, Priority Technology and Kingstone - Yahoo Finance
JPMorgan Initiates ANI Pharmaceuticals at Overweight With $85 Price Target -March 12, 2025 at 07:10 am EDT - Marketscreener.com
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of “Buy” by Analysts - Defense World
ANI Pharmaceuticals at Leerink Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
ANI Pharmaceuticals Discusses Alimera Acquisition Challenges - TipRanks
Ani Pharmaceuticals’ chief HR officer Krista Davis sells $60,860 in stock - Investing.com Canada
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call Transcript - MSN
Don't Ignore The Insider Selling In ANI Pharmaceuticals - Simply Wall St
Top Executive at ANI Pharmaceuticals Sells Thousands in Stock! - TipRanks
Ani Pharmaceuticals SVP sells $323,049 in stock By Investing.com - Investing.com UK
ANI Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis - MarketBeat
Q1 Earnings Estimate for ANIP Issued By HC Wainwright - Defense World
ANI Pharma at Raymond James Conference: Strategic Shift to Rare Diseases - Investing.com Canada
7.85%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):